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Conclusions: Our results suggest that appropriate dose adjustments 
by reducing the intervals of IFX dosing may overcome low ADA 
titers with the aim to maintain or restore clinical response. In add-
ition, proactive evaluation of ADA status may allow earlier identifi-
cation of patients prone to a loss of response. The implementation of 
Bayesian dashboards may assist in the prediction of SICs <3 μg and 
determining adequate dosing modifications.
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Background: Granulomatous (GL) and interstitial lung disease (ILD) 
are rare respiratory disorders that have been associated with inflam-
matory bowel disease (IBD). Clinical presentation is polymorphic 
and aetiology is unclear.
Methods: This was European Crohn’s and colitis organisation 
(ECCO) retrospective observational study performed as part of 
CONFER project. A call to all ECCO members was made to report 
concomitant granulomatous or ILD and IBD cases. Clinical data 
were recorded in a standardised case report form.
Results: Twenty-two granulomatous lung disease patients were iden-
tified from 18 university hospitals, 17 males and 5 females with a 
mean age of 46 years (18–86); 17 patients with Crohn’s disease (CD) 
and five with ulcerative colitis (UC). In 19 patients IBD diagnosis 
preceded lung disease in a median time of 10.6 years (0–27). In three 
patients lung disease were diagnosed in a median time of 14 months 
(8–24) before IBD. Only four patients had active disease. Seven 
patients had drug-related granulomatous disease (sarcoidosis n = 4) 
and 14 had non-drug-related GL (primary sarcoidosis n = 7, fungal 
infection n = 2 and unspecified n = 5). Ten patients (45%) required 
hospitalisation but none required invasive ventilation. Fifteen of 22 
patients received systemic steroids and causative drug was stopped 
in all patients. At further follow-up, 15 of 22 patients had no re-
spiratory symptoms. Thirty-one patients with ILD were identified 
from 14 medical centres, 12 females and 19 males with mean age 
of 47 years (17–84); eight patients had CD, 22 had UC and one had 
indeterminate colitis. All patients had IBD diagnosis prior to ILD 
with a median time of 10.27 years (0.3–51). Eight patients had active 
disease. Eleven patients had non-drug-related ILD and 20 had drug-
related ILD (mesalazine n = 9, methotrexate n = 1, golimumab n = 1, 
vedolizumab n = 1 and infliximab n = 8). ILD cases were classified 
as: Cryptogenic organising pneumonia n = 11, Eosinophilic pneu-
monitis n = 2, bronchiolitis n = 2, acute interstitial pneumonia n = 8, 
interstitial lung disease due to connective tissue n  =  1, idiopathic 
fibrosis n = 6 and unclassified n = 1. Twenty-five patients (80.6%) 
required hospitalisation and one required non-invasive ventilation. 
Twenty-seven patients (87%) received systemic steroids and causa-
tive drug was stopped in all patients. At further follow-up, 14 of 31 
patients had no respiratory symptoms, 7 of 31 had some improve-
ment, and 4 of 31 had ongoing symptoms. There was one patient 
referred for consideration of lung transplant due to progressive fi-
brosis and one death due to mesalazine.
Conclusions: GL and ILD are rare, but require hospitalisation and 
systemic steroids. In our case series half of cases were drug-related 
but there was no signal of relationship between IBD therapy and the 
onset of ILD. More studies are needed to investigate the pathogenesis 
and causative association.
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Background: Microbial dysbiosis is believed to play a role in Crohn's 
disease (CD). Most data are derived from CD patients under medica-
tions, an exposure that might impact microbial composition. Our 
aim was to assess microbial dysbiosis in patients with newly diag-
nosed CD and correlate it with disease activity.
Methods: Newly diagnosed CD patients were prospectively recruited 
and followed longitudinally. Clinical data, disease activity (physician 
global assessment [PGA] ranging from 0 to 3), and serum and fae-
cal inflammatory biomarkers, were collected. Faecal samples were 
assessed for microbial composition using 16S rRNA sequencing. The 
microbial dysbiosis index (MDI) was used to quantify the degree of 
dysbiosis per sample.
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